Compugen Ltd. (NASDAQ:CGEN) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Compugen Ltd. (NASDAQ:CGEN) has been given a consensus rating of “Moderate Buy” by the five ratings firms that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, three have issued a buy rating and one has given a strong buy rating to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $5.00.

Several equities research analysts have recently commented on CGEN shares. Truist Financial raised shares of Compugen to a “strong-buy” rating in a research report on Wednesday, March 25th. Weiss Ratings reissued a “sell (d-)” rating on shares of Compugen in a research report on Monday, April 20th. Wall Street Zen downgraded shares of Compugen from a “buy” rating to a “hold” rating in a research report on Saturday, May 23rd. Leerink Partners reduced their price objective on shares of Compugen from $13.00 to $5.00 and set an “outperform” rating for the company in a research report on Thursday, May 21st. Finally, Lake Street Capital began coverage on shares of Compugen in a research report on Tuesday, April 7th. They issued a “buy” rating and a $6.00 price objective for the company.

Institutional Investors Weigh In On Compugen

A number of institutional investors have recently added to or reduced their stakes in CGEN. Franklin Resources Inc. bought a new stake in Compugen in the 2nd quarter worth about $56,000. Jane Street Group LLC grew its position in Compugen by 1,077.0% in the 2nd quarter. Jane Street Group LLC now owns 393,191 shares of the biotechnology company’s stock worth $700,000 after purchasing an additional 359,785 shares in the last quarter. Osaic Holdings Inc. grew its position in Compugen by 346.0% in the 2nd quarter. Osaic Holdings Inc. now owns 43,885 shares of the biotechnology company’s stock worth $78,000 after purchasing an additional 34,045 shares in the last quarter. Two Sigma Investments LP grew its position in Compugen by 10.6% in the 3rd quarter. Two Sigma Investments LP now owns 197,875 shares of the biotechnology company’s stock worth $291,000 after purchasing an additional 18,929 shares in the last quarter. Finally, Raymond James Financial Inc. grew its position in Compugen by 51.0% in the 3rd quarter. Raymond James Financial Inc. now owns 101,256 shares of the biotechnology company’s stock worth $149,000 after purchasing an additional 34,215 shares in the last quarter. 12.22% of the stock is owned by institutional investors.

Compugen Price Performance

NASDAQ:CGEN opened at $2.04 on Monday. The firm has a 50-day moving average of $2.61 and a 200-day moving average of $2.10. The company has a market cap of $192.88 million, a PE ratio of 5.51 and a beta of 2.74. Compugen has a one year low of $1.29 and a one year high of $3.23.

Compugen (NASDAQ:CGEN) last posted its earnings results on Monday, May 18th. The biotechnology company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.01). The business had revenue of $2.18 million for the quarter, compared to the consensus estimate of $1.57 million. Compugen had a return on equity of 47.72% and a net margin of 47.97%. On average, equities research analysts expect that Compugen will post -0.28 earnings per share for the current fiscal year.

Compugen Company Profile

Compugen Ltd. (NASDAQ: CGEN) is a clinical-stage therapeutic discovery company that leverages proprietary computational discovery platforms to identify novel immuno-oncology targets and biomarkers. The company combines large-scale biological datasets with machine learning algorithms to generate and validate new therapeutic and diagnostic candidates. Founded in 1993 and headquartered in Tel Aviv, Israel, Compugen also maintains a presence in the United States to support its clinical development and commercial collaborations.

Compugen’s predictive discovery engine scans complex biological systems in silico to reveal previously unrecognized pathways and immune checkpoints involved in cancer progression.